Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploration of the Clinical Application of Almonertinib in the First-line Treatment of Patients With EGFR Mutation-positive Advanced Non-small Cell Lung Cancer With Poor Performance Status

NCT05826483 is registered in ClinicalTrials.gov with Guangzhou Institute of Respiratory Disease as lead sponsor.

NCT NCT05826483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05826483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploration of the Clinical Application of Almonertinib in the First-line Treatment of Patients With EGFR Mutation-positive Advanced Non-small Cell Lung Cancer With Poor Performance Status
Lead sponsor
Guangzhou Institute of Respiratory Disease
Phase
Phase 1
Overall status
Unknown status
Start date
January 1, 2022
Completion date
December 30, 2024
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant tumor of lung, poor performance status